EIF4G1 and non-small cell lung carcinoma: To seek treatment benefits, we will explore whether EIF4G1 targeted therapy may improve immunotherapy (eg Pembrolizumab) in a new humanized NSCLC‐PDX (Patient‐derived xenograft) mice model recently established from the Jackson Laboratory.34